Study of RO7673396 for advanced solid tumors with RAS mutations
Part of Cancer clinical trials.
This trial tests a new drug, RO7673396, for people with advanced solid tumors that have a RAS mutation. The goal is to see if the drug is safe and works against the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have an advanced solid tumor that cannot be removed by surgery or has spread
- Your tumor has a RAS mutation (confirmed by a lab test)
- Your cancer can be measured on scans (RECIST criteria)
- You are able to take care of yourself (ECOG score 0 or 1)
- You have not had certain other cancer treatments in the last 4 weeks
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether RMC-6236 can treat advanced solid tumors that have specific RAS-related gene changes (especially certain KRAS G12 mutations). You may be able to join if your tumor’s DNA test shows the right mutation and your overall health is good enough for study visits.
This trial tests a new drug called RLY-8161 in people with advanced solid tumors (cancer that has spread) that have a specific genetic mutation called NRAS. The drug is designed to target this mutation and may help slow or shrink tumors that haven't responded to standard treatments.
This trial tests a new drug, HRS-7172, for people with advanced solid tumors that have RAS mutations or amplifications. It aims to see if the drug is safe and effective for these cancers.
This trial is testing a new drug called BG-85738, which may target cancer cells that have a specific change (mutation) in the RAS gene. The goal is to see if it is safe and works against advanced or spreading solid tumors.
This trial tests new drugs that target specific RAS mutations in advanced gastrointestinal cancers, like pancreatic or colorectal cancer. It aims to see if these drugs can shrink tumors or slow their growth.
This trial tests a new drug, HRS-2329, for people with advanced solid tumors that have a RAS mutation or amplification and haven't responded to standard treatments. It aims to see if the drug can help shrink or control the tumors.
Hear when a new Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.